The rise of AI in drug discovery is being overstated, with the diseases that remain unsolved. At Novartis, researchers used generative AI to design 15 million potential compounds for Huntington's disease, a type of molecule that could cross the blood-brain barrier and attack a protein implicated in the illness. The gap between what AI can do in a laboratory and what it has actually delivered to patients is the defining tension of health technology in 2026. As of January 2024, at least 75 drugs or vaccines from AI-first biotechs had entered clinical trials. However, as of December 2025, no AI-discovered drug has received FDA approval. The pharmaceutical industry's 90% clinical failure rate has not significantly improved.